Epsilon M&A Deal Report - Oncodesign Services (ODS)
Transaction Multiples for the Valuation of Private Companies
Private group led by Edmond de Rothschild Private Equity / Oncodesign Services (ODS)
No EMAT :
114507
Announced Date :
01/07/2022
Type :
MBO (Management Buy Out) ,P2P (Public to Private)
Deal Value :
Yes
Acquirer :
Private group led by Edmond de Rothschild Private Equity
Target :
Oncodesign Services (ODS)
Country :
Côte-D'Or
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Laboratory Testing Services
Business Description :
Oncodesign Services is a CRO specializing in drug discovery and preclinical services in oncology and immuno-inflammation. > World-renowned expertise in the preclinical evaluation of proof of concept...
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|||||
| Current |
|
|
|
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Laboratory Testing Services » = 36
| Date | Acquirer | Target | Country | Multiples | See details |
| 02/11/2021 | Private group led by KKR & Co. Inc | Biosynth Beteilingungs | Switzerland | ** | 114416 |
| 24/05/2022 | Gallus (renamed Biosynth) | Aalto Bio | Ireland | ** | 114403 |
Source: Epsilon Research / EMAT
